<DOC>
	<DOCNO>NCT00502840</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety repeat course MabThera patient active rheumatoid arthritis participate ML19070 , complete week 24 visit . Eligible patient ( DAS28 &gt; 2.6 week 24 ) , receive 2 infusion 1g MabThera ( Day 1 day 15 ) . For patient extension study , 3 repeat course treatment allow . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Re-Treatment With MabThera ( Rituximab ) Patients With Rheumatoid Arthritis Who Have Had Inadequate Response Single Anti-TNF Inhibitor .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient rheumatoid arthritis participate ML19070 , complete week 24 visit ; eligible retreatment ( DAS28 &gt; 2.6 week 24 , swell joint count &gt; =4 , tender joint count &gt; =4 ) . patient withdraw treatment ML19070 preweek 16 ; patient previous response DAS28 &lt; 0.6 MabThera week 16 ; concurrent treatment DMARD except methotrexate , TNF alpha inhibitor , biologic investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>